A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Servier
Pfizer
Eli Lilly and Company
Hummingbird Bioscience
Novartis
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Fate Therapeutics
Alterome Therapeutics, Inc.
Novartis
Revolution Medicines, Inc.
Pfizer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
BeOne Medicines
AstraZeneca
Incyte Corporation
Pfizer
Tizona Therapeutics, Inc
Genentech, Inc.
SWOG Cancer Research Network
Revolution Medicines, Inc.
Jacobio Pharmaceuticals Co., Ltd.
Memorial Sloan Kettering Cancer Center
PAQ Therapeutics, Inc.
Bristol-Myers Squibb
Bristol-Myers Squibb
Genentech, Inc.
Eli Lilly and Company
Genfleet Therapeutics (Shanghai) Inc.
Bristol-Myers Squibb
InventisBio Co., Ltd
Innovent Biologics (Suzhou) Co. Ltd.
Pfizer
GlaxoSmithKline
University of Turin, Italy
The Netherlands Cancer Institute
The Netherlands Cancer Institute
University of California, Davis
Fate Therapeutics
Eastern Cooperative Oncology Group
University of Alabama at Birmingham
SWOG Cancer Research Network
Eli Lilly and Company
Intergroupe Francophone de Cancerologie Thoracique
Radiation Therapy Oncology Group
Merck KGaA, Darmstadt, Germany
Swiss Cancer Institute
Eli Lilly and Company